Davorka Tomic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Davorka Tomic has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Ludwig Kappos
University Hospital Basel, Switzerland
6 shared publications - Frank Dahlke
Novartis Pharma AG, Basel, Switzerland
5 shared publications Daniela Piani Meier
Novartis Pharma AG Basel Switzerland
4 shared publications- Jeffrey A. Cohen
Mellen Center, Neurologic Institute, Cleveland Clinic, Cleveland, USA
3 shared publications Shannon Ritter
Novartis Pharmaceuticals Corporation East Hanover NJ United States
3 shared publications- Xavier Montalban
Centro de Esclerosis Múltiple de Cataluña y Departamento de Neurología, Hospital Universitario Vall d’Hebron, 08035 Barcelona, España
3 shared publications
Latest Publications
- Top Cited Papers
- 19 September 2024
- Published by Elsevier in The Lancet Neurology
- Vol. 23 (11) , 1119-1132
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
- 19 September 2024
- Published by Elsevier in The Lancet Neurology
- Vol. 23 (11) , 1119-1132
Top Cited PapersSafety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
- 27 March 2023
- Published by Elsevier in Revue Neurologique
- Vol. 179, S150
Résultats cliniques et d’imagerie par résonance magnétique de l’évobrutinib (EVO), un inhibiteur de la tyrosine kinase de Bruton (BTKi), dans le traitement de la sclérose en plaques récurrente (SEP-R) sur une période de 2,5 ans dans l’extension en ouvert
- 27 March 2023
- Published by Elsevier in Revue Neurologique
- Vol. 179, S150
Résultats cliniques et d’imagerie par résonance magnétique de l’évobrutinib (EVO), un inhibiteur de la tyrosine kinase de Bruton (BTKi), dans le traitement de la sclérose en plaques récurrente (SEP-R) sur une période de 2,5 ans dans l’extension en ouvert
- Open Access
- 14 April 2020
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 8 (4) , e17592
A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm
Background: There is an unmet need for a tool that helps to evaluate patients who are at risk of progressing from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis (SPMS). A new tool supporting the evaluation of early signs suggestive of progression in multiple sclerosis (MS) has been developed. In the initial stage, concepts relevant to progression were identified using a mixed method approach involving regression on data from a real-world observational study and qualitative research with patients and physicians. The tool was drafted in a questionnaire format to assess these variables. Objective: This study aimed to develop the scoring algorithm for the tool, using both quantitative and qualitative research methods. Methods: The draft scoring algorithm was developed using two approaches: quantitative analysis of real-world data and qualitative analysis based on physician interviews and ranking and weighting exercises. Variables that were included in the draft tool and regarded as most clinically relevant were selected for inclusion in a multiple logistic regression. The analyses were run using physician-reported data and patient-reported data. Subsequently, a ranking and weighting exercise was conducted with 8 experienced neurologists as part of semistructured interviews. Physicians were presented with the variables included in the draft tool and were asked to rank them in order of strength of contribution to progression and assign a weight by providing a percentage of the overall contribution. Physicians were also asked to explain their ranking and weighting choices. Concordance between physicians was explored. Results: Multiple logistic regression identified age, MS disease activity, and Expanded Disability Status Scale score as the most significant physician-reported predictors of progression to SPMS. Patient age, mobility, and self-care were identified as the strongest patient-reported predictors of progression to SPMS. In physician interviews, the variables ranked and weighted as most important were stability or worsening of symptoms, intermittent or persistent symptoms, and presence of ambulatory and cognitive symptoms. Across all physicians, the level of concordance was 0.278 (P<.001), indicating a low to moderate, but statistically significant, level of agreement. Variables were categorized as high (n=8), moderate (n=8), or low (n=10) importance based on the findings from the different approaches described above. Accordingly, the respective questions in the tool were assigned a weight of “three,” “two,” or “one” to inform the draft scoring algorithm. Conclusions: This study further confirms the need for a tool to provide a consistent, comprehensive approach across physicians to support the early evaluation of signs indicative of progression to SPMS. The novel and comprehensive approach to develop the draft scoring algorithm triangulates data obtained from ranking and weighting exercises, qualitative interviews, and a real-world observational study. Variables that go beyond the clinically most obvious impairment in lower limbs have been identified as relevant subtle/sensitive signs suggestive of progressive disease.
- 14 April 2020
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 8 (4) , e17592
Open AccessA Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm
Background: There is an unmet need for a tool that helps to evaluate patients who are at risk of progressing from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis (SPMS). A new tool supporting the evaluation of early signs suggestive of progression in multiple sclerosis (MS) has been developed. In the initial stage, concepts relevant to progression were identified using a mixed method approach involving regression on data from a real-world observational study and qualitative research with patients and physicians. The tool was drafted in a questionnaire format to assess these variables. Objective: This study aimed to develop the scoring algorithm for the tool, using both quantitative and qualitative research methods. Methods: The draft scoring algorithm was developed using two approaches: quantitative analysis of real-world data and qualitative analysis based on physician interviews and ranking and weighting exercises. Variables that were included in the draft tool and regarded as most clinically relevant were selected for inclusion in a multiple logistic regression. The analyses were run using physician-reported data and patient-reported data. Subsequently, a ranking and weighting exercise was conducted with 8 experienced neurologists as part of semistructured interviews. Physicians were presented with the variables included in the draft tool and were asked to rank them in order of strength of contribution to progression and assign a weight by providing a percentage of the overall contribution. Physicians were also asked to explain their ranking and weighting choices. Concordance between physicians was explored. Results: Multiple logistic regression identified age, MS disease activity, and Expanded Disability Status Scale score as the most significant physician-reported predictors of progression to SPMS. Patient age, mobility, and self-care were identified as the strongest patient-reported predictors of progression to SPMS. In physician interviews, the variables ranked and weighted as most important were stability or worsening of symptoms, intermittent or persistent symptoms, and presence of ambulatory and cognitive symptoms. Across all physicians, the level of concordance was 0.278 (P<.001), indicating a low to moderate, but statistically significant, level of agreement. Variables were categorized as high (n=8), moderate (n=8), or low (n=10) importance based on the findings from the different approaches described above. Accordingly, the respective questions in the tool were assigned a weight of “three,” “two,” or “one” to inform the draft scoring algorithm. Conclusions: This study further confirms the need for a tool to provide a consistent, comprehensive approach across physicians to support the early evaluation of signs indicative of progression to SPMS. The novel and comprehensive approach to develop the draft scoring algorithm triangulates data obtained from ranking and weighting exercises, qualitative interviews, and a real-world observational study. Variables that go beyond the clinically most obvious impairment in lower limbs have been identified as relevant subtle/sensitive signs suggestive of progressive disease.
- Open Access
- 12 February 2020
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 22 (2) , e16932
A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study
Background: Defining the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) can be challenging and delayed. A digital tool (MSProDiscuss) was developed to facilitate physician-patient discussion in evaluating early, subtle signs of multiple sclerosis (MS) disease progression representing this transition.Objective: This study aimed to determine cut-off values and corresponding sensitivity and specificity for predefined scoring algorithms, with or without including Expanded Disability Status Scale (EDSS) scores, to differentiate between RRMS and SPMS patients and to evaluate psychometric properties.Methods: Experienced neurologists completed the tool for patients with confirmed RRMS or SPMS and those suspected to be transitioning to SPMS. In addition to age and EDSS score, each patient’s current disease status (disease activity, symptoms, and its impacts on daily life) was collected while completing the draft tool. Receiver operating characteristic (ROC) curves determined optimal cut-off values (sensitivity and specificity) for the classification of RRMS and SPMS.Results: Twenty neurologists completed the draft tool for 198 patients. Mean scores for patients with RRMS (n=89), transitioning to SPMS (n=47), and SPMS (n=62) were 38.1 (SD 12.5), 55.2 (SD 11.1), and 69.6 (SD 12.0), respectively (P<.001, each between-groups comparison). Area under the ROC curve (AUC) including and excluding EDSS were for RRMS (including) AUC 0.91, 95% CI 0.87-0.95, RRMS (excluding) AUC 0.88, 95% CI 0.84-0.93, SPMS (including) AUC 0.91, 95% CI 0.86-0.95, and SPMS (excluding) AUC 0.86, 95% CI 0.81-0.91. In the algorithm with EDSS, the optimal cut-off values were ≤51.6 for RRMS patients (sensitivity=0.83; specificity=0.82) and ≥58.9 for SPMS patients (sensitivity=0.82; specificity=0.84). The optimal cut-offs without EDSS were ≤46.3 and ≥57.8 and resulted in similar high sensitivity and specificity (0.76-0.86). The draft tool showed excellent interrater reliability (intraclass correlation coefficient=.95).Conclusions: The MSProDiscuss tool differentiated RRMS patients from SPMS patients with high sensitivity and specificity. In clinical practice, it may be a useful tool to evaluate early, subtle signs of MS disease progression indicating the evolution of RRMS to SPMS. MSProDiscuss will help assess the current level of progression in an individual patient and facilitate a more informed physician-patient discussion.
- 12 February 2020
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 22 (2) , e16932
Open AccessA Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study
Background: Defining the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) can be challenging and delayed. A digital tool (MSProDiscuss) was developed to facilitate physician-patient discussion in evaluating early, subtle signs of multiple sclerosis (MS) disease progression representing this transition.Objective: This study aimed to determine cut-off values and corresponding sensitivity and specificity for predefined scoring algorithms, with or without including Expanded Disability Status Scale (EDSS) scores, to differentiate between RRMS and SPMS patients and to evaluate psychometric properties.Methods: Experienced neurologists completed the tool for patients with confirmed RRMS or SPMS and those suspected to be transitioning to SPMS. In addition to age and EDSS score, each patient’s current disease status (disease activity, symptoms, and its impacts on daily life) was collected while completing the draft tool. Receiver operating characteristic (ROC) curves determined optimal cut-off values (sensitivity and specificity) for the classification of RRMS and SPMS.Results: Twenty neurologists completed the draft tool for 198 patients. Mean scores for patients with RRMS (n=89), transitioning to SPMS (n=47), and SPMS (n=62) were 38.1 (SD 12.5), 55.2 (SD 11.1), and 69.6 (SD 12.0), respectively (P<.001, each between-groups comparison). Area under the ROC curve (AUC) including and excluding EDSS were for RRMS (including) AUC 0.91, 95% CI 0.87-0.95, RRMS (excluding) AUC 0.88, 95% CI 0.84-0.93, SPMS (including) AUC 0.91, 95% CI 0.86-0.95, and SPMS (excluding) AUC 0.86, 95% CI 0.81-0.91. In the algorithm with EDSS, the optimal cut-off values were ≤51.6 for RRMS patients (sensitivity=0.83; specificity=0.82) and ≥58.9 for SPMS patients (sensitivity=0.82; specificity=0.84). The optimal cut-offs without EDSS were ≤46.3 and ≥57.8 and resulted in similar high sensitivity and specificity (0.76-0.86). The draft tool showed excellent interrater reliability (intraclass correlation coefficient=.95).Conclusions: The MSProDiscuss tool differentiated RRMS patients from SPMS patients with high sensitivity and specificity. In clinical practice, it may be a useful tool to evaluate early, subtle signs of MS disease progression indicating the evolution of RRMS to SPMS. MSProDiscuss will help assess the current level of progression in an individual patient and facilitate a more informed physician-patient discussion.
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Fingolimod significantly lowers neurofilament light chain blood levels in RRMS patients as compared to interferon beta-1a or placebo (P6.376)
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Fingolimod significantly lowers neurofilament light chain blood levels in RRMS patients as compared to interferon beta-1a or placebo (P6.376)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
The Timed 25-foot Walk Test as an Alternative to EDSS Score for Evaluating ‘No Evidence of Disease of Activity’ (NEDA-4) Status in Patients with RRMS (P2.143)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
The Timed 25-foot Walk Test as an Alternative to EDSS Score for Evaluating ‘No Evidence of Disease of Activity’ (NEDA-4) Status in Patients with RRMS (P2.143)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Long-Term Effect of Fingolimod on Disability: A Categorical Trend Analysis Over 8 Years (P3.080)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Long-Term Effect of Fingolimod on Disability: A Categorical Trend Analysis Over 8 Years (P3.080)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
MRI Parameters as Predictors of Long-Term Disease Outcome Over 8 Years in RRMS Patients (S51.008)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
MRI Parameters as Predictors of Long-Term Disease Outcome Over 8 Years in RRMS Patients (S51.008)
- 6 April 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (14_supplem)
Effect of fingolimod versus interferon-beta1a on no evidence of disease activity or worsening (NEDA-4) in the TRANSFORMS study (P4.001)
- 6 April 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (14_supplem)
Effect of fingolimod versus interferon-beta1a on no evidence of disease activity or worsening (NEDA-4) in the TRANSFORMS study (P4.001)
- 12 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)
Effect of Fingolimod in Patients with No Disability as Measured by EDSS at Baseline: Post-Hoc Analyses of FREEDOMS I and II (P07.124)
- 12 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)
Effect of Fingolimod in Patients with No Disability as Measured by EDSS at Baseline: Post-Hoc Analyses of FREEDOMS I and II (P07.124)